Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer
- 30 April 2009
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 64 (1), 51-59
- https://doi.org/10.1016/j.lungcan.2008.07.002
Abstract
No abstract availableKeywords
This publication has 66 references indexed in Scilit:
- First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutationsJournal of Clinical Oncology, 2008
- Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?British Journal of Cancer, 2007
- A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutationsBritish Journal of Cancer, 2006
- Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene MutationsJournal of Clinical Oncology, 2006
- Hormone Replacement Therapy Is Associated With Decreased Survival in Women With Lung CancerJournal of Clinical Oncology, 2006
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004